15 February 2022 : Original article
Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT)
Katarzyna Zielińska1ABCDEF*, Leszek Kukulski
2ACDF, Marta Wróbel1AF, Piotr Przybyłowski3ACDF, Dominika Rokicka1AF, Krzysztof Strojek1ACDE
DOI: 10.12659/AOT.933420
Ann Transplant 2022; 27:e933420
Table 1 Characteristics of the sample group divided into 4 subgroups (Excel by Microsoft 365).
| Division | ||||
|---|---|---|---|---|
| Without diabetes | Diabetes type 2 | Hyperglycemia | NODAT | |
| Number of patients | 299 (62.7%) | 68 (14.3%) | 22 (4.6%) | 88 (18.4%) |
| Recipient sex (male) – no. (%) | 245 (81.9%) | 57 (83.8%) | 15 (68.2%) | 70 (79.6%) |
| Recipient age – years | 42.7±14.2 | 52.7±8.2 | 46.5±11.7 | 52.2±10.3 |
| BMI – kg/m | ||||
| BMI at discharge | 23.3±3.5 | 25.6±3.3 | 25.6±3.3 | 25.6±3.3 |
| BMI at 1y follow-up | 25.3±4.0 | 27.5±4.0 | 27.5±4.0 | 27.5±4.0 |
| BMI at last available follow-up | 26.0±4.8 | 28.3±4.2 | 28.3±4.2 | 28.3±4.2 |
| Increase in body weight in 2y after OHT by more than 5 kg – no. (%) | 230 (76.9%) | 43 (63.2%) | 14 (63.6%) | 42 (47.7%) |
| Ischemic – no. (%) | 94 (31.4%) | 34 (50%) | 9 (40.9%) | 52 (59.9%) |
| eGFR – mL/min/1.73 m | 94.0±40.0 | 79.4±30.6 | 90.9±27.5 | 78.8±29.9 |
| Dyslipidemia – no. (%) | 52 (17.4%) | 27 (39.7%) | 9 (40.9%) | 30 (34.1%) |
| CMV seropositivity - no. (%) | 52 (17.4%) | 19 (28.0%) | 3 (13.6%) | 20 (22.7%) |
| Hypotensive pharmacotherapy – no. (%) | 40 (13.4%) | 14 (20.6%) | 8 (36.4%) | 25 (28.4%) |
| Levothyroxine therapy – no. (%) | 29 (9.7%) | 5 (7.4%) | 1 (4.50%) | 10 (11.4%) |
| Cyclosporine immunosuppressive scheme – no. (%) | 38 (12.71%) | 11 (16.18%) | 11 (50%) | 25 (28.41%) |
| Statins therapy – no. (%) | 148 (49.5%) | 45 (66.18%) | 18 (81.8%) | 73 (82.95%) |
| Steroid therapy | ||||
| 6 mth posttransplant | 150 (50.2%) | 54 (79.41%) | 22 (100%) | 80 (90.91%) |
| 12 mth posttransplant | 62 (20.7%) | 25 (36.8%) | 13 (59.1%) | 23 (26.1%) |
| 24 mth posttransplant | 17 (5.7%) | 11 (16.2%) | 8 (36.4%) | 9 (10.2%) |
| ISHLT >3a at discharge – no. (%) | 96 (20.1%) | 28 (5.9%) | 16 (3.4%) | 52 (10.9%) |
| The episode numer of ISHLT >3a during the 1 year post-transplantation – no. (%) | ||||
| 0 | 91 (30.4%) | 23 (33.8%) | 3 (13.6%) | 29 (33%) |
| 1 | 73 (24.4%) | 26 (38.2%) | 12 (54.5%) | 30 (34.1%) |
| 2 | 55 (18.4%) | 6 (8.8%) | 4 (18.2%) | 16 (18.2%) |
| 3 | 44 (14.7%) | 3 (4.4%) | 1 (4.5%) | 9 (10.2%) |
| 4 | 19 (6.4%) | 5 (7.4%) | 2 (9.1%) | 4 (4.5%) |
| 5 | 11 (3.7%) | 1 (1.5%) | 0 (0.0%) | 0 (0.0%) |
| 6 | 2 (0.7%) | 3 (4.4%) | 0 (0.0%) | 0 (0.0%) |
| 7 | 2 (0.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 8 | 1 (0.3%) | 1 (1.5%) | 0 (0.0%) | 0 (0.0%) |